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Abstract
Background: Long noncoding RNAs (lncRNAs) are an emerging class of relatively
underexplored oncogenic molecules with biological and clinical significance. Current
inadequacies for stratifying patients with aggressive disease presents a strong rationale
to systematically identify lncRNAs as clinical predictors in localized prostate cancer.
Objective: To identify RNA biomarkers associated with aggressive prostate cancer.
Design, setting, and participants: Radical prostatectomy microarray and clinical data
was obtained from 910 patients in three published institutional cohorts: Mayo Clinic I
(N = 545, median follow-up 13.8 yr), Mayo Clinic II (N = 235, median follow-up 6.7 yr),
and Thomas Jefferson University (N = 130, median follow-up 9.6 yr).
Outcome measurements and statistical analysis: The primary clinical endpoint was
distant metastasis-free survival. Secondary endpoints include prostate cancer-speciﬁc
survival and overall survival. Univariate and multivariate Cox regression were used to
evaluate the association of lncRNA expression and these endpoints.
Results and limitations: An integrative analysis revealed Prostate Cancer Associated
Transcript-14 (PCAT-14) as the most prevalent lncRNA that is aberrantly expressed in
prostate cancer patients. Down-regulation of PCAT-14 expression signiﬁcantly associat-
ed with Gleason score and a greater probability of metastatic progression, overall
survival, and prostate cancer-speciﬁc mortality across multiple independent datasets
and ethnicities. Low PCAT-14 expression was implicated with genes involved in biologi-
cal processes promoting aggressive disease. In-vitro analysis conﬁrmed that low PCAT-
14 expression increased migration while overexpressing PCAT-14 reduced cellular
growth, migration, and invasion.
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The majority of prostate cancer patients are diagnosed at a
potentially curable stage and are often treated with radical
prostatectomy or other first-line treatments [1]. However, a
subset of patients with aggressive disease face the risk of
prostate cancer recurrence, which can manifest as persis-
tently elevated/increasing serum prostate-specific antigen
or metastasis. Therefore, a critical goal in prostate cancer
research is determining the molecular underpinnings of
aggressive and indolent disease to improve patient man-
agement and prognosis. Recent studies demonstrated the
utility of protein-coding genes as prognostic biomarkers
[2,3]. However, the lack of tissue specificity hinders the
ability to monitor their expression levels noninvasively. In
contrast, long noncoding RNAs (lncRNAs) are used success-
fully to diagnosis and risk stratify prostate cancer
[4,5]. Therefore, our study focuses on exploring lncRNAs
as biomarkers for risk stratification to ultimately improve
patient management.
Our group and others have leveraged next-generation
sequencing to generate an unbiased transcriptome to
discover novel lncRNAs in prostate cancer [6–8]. This has
spurred numerous studies exploring the biological and
clinical significance of lncRNAs [5,9,10]. However, to date,
all of the transcriptome-based discoveries have utilized
patient samples fromhigh quality specimens (ie, abundance
of tissue, snap frozen tissue, recently collected), which
made them ideal to perform transcriptome sequencing but
lacked longer-term clinical outcomes. To address this, we
performed an integrative analysis of multiple independent
transcriptome data collections [7,11,12] coupled with an
unconventional microarray platform, with probe coverage
of a significant portion of lncRNAs, to associate lncRNA
expression with long-term outcomes such as metastasis,
overall survival, and prostate-cancer specific mortality.
2. Patients and methods
2.1. Clinical association of PCAT-14
Microarray data was obtained from four previously published datasets
from the DecipherGenomic Resource Information Database [13–16]. Data
can also be found in theGene ExpressionOmnibus: GSE29079, GSE46691,
GSE62116, and GSE72291. Cancer versus normal analysis was performed
in the pooled cohorts by Brase et al [13]. Clinical endpoints were
evaluated in the Mayo Clinic I and II (MCI and II) cohorts and the Thomas
JeffersonUniversity (TJU) cohort. TheMCI cohort consisted of 545patients
from a nested case control study with matched triplets for no recurrence,
biochemical recurrence only, and metastasis after prostatectomy. The
MCII cohort consisted of a case-cohort studywith a 20% random samplingfrom 1010 men with high-risk prostate cancer that was enriched with all
of the remaining metastatic cases from the 80% of men not sampled
resulting in 235 patients. Postsurgical therapies for both Mayo cohorts
were at the treating physician’s discretion. The TJU cohort consisted of
130 patients with pT3 or margin-positive disease who received
postoperative radiation therapy, with hormone therapy at the treating
physician’s discretion. PCAT-14 expression was calculated by taking the
mean expression of probe sets mapping to exons. A Student’s t-test was
used to test differences in expression between cancer and normal
samples. High/low PCAT-14 expressionwas determined by splitting at the
median expression level. Kaplan-Meier curves are shown and statistical
inference was performed using the Log-rank test. Addition of PCAT-14 to
Cancer of the Prostate Risk Assessment Postsurgical score (CAPRA-S)
[17,18] was obtained by training a logistic regression model with both
variables, and the model predictions were compared with CAPRA-S alone
[5]. Time-dependent receiver operating curves and the area under the
curve was calculated using the ‘‘timeROC’’ R package (by Paul Blanche).
Multivariable analysis was performed using Cox regression stratiﬁed by
cohort to adjust for baseline differences. Association of PCAT-14 with
clinicopathologic variableswas performed and statistical associationwith
continuous variables was assessed using a Student t-test, and categorical
variables with the chi-square test. All statistical tests were two-sided and
signiﬁcance was set as p< 0.05. Our study adheres to Reporting
recommendations for tumor marker prognostic studies criteria [19].
3. Results
3.1. Integrative lncRNA analysis
To identify consistently altered lncRNAs during prostate
cancer progression, we performed an integrative analysis of
three patient cohorts (Supplementary Table 1): (1) tran-
scriptome sequencing of 14 primary tumors and matched
adjacent normal tissue (Ren et al cohort) [7], (2) tran-
scriptome sequencing of 20 primary tumors and10matched
adjacent normal tissues (Kannan et al cohort) [12], and (3)
Affymetrix gene expression of 131 primary and 19 meta-
static tumors (Taylor et al cohort) [11]. Four lncRNAs were
up-regulated and one lncRNAwas down-regulated between
the primary tumors and normal tissue across all three
cohorts (Fig. 1A, Supplementary Tables 2–5).
Leveraging the clinical data associated with the Taylor
et al cohort [11], we next assessed if the lncRNAs were
associated with aggressive disease based on Gleason score.
While multiple candidates are reported to have altered
expression in prostate tumors (ie, DRAIC [9], PCAT-14 [6],
PCAT-101 [6]), PCAT-14 was the only lncRNA significantly
down-regulated in patients with high (9) relative to low (6)
Gleason scores (p = 0.00013; Fig. 1B, Supplementary
Table 2) and negatively correlated with Gleason score
(correlation = 0.22). Confirming earlier findings [6], PCAT-
14 displayed altered expression throughout prostate tumor
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Fig. 1 – Integrative analysis reveals Prostate Cancer Associated Transcript-14 (PCAT-14) expression associates with prostate cancer. (A) Differentially
expressed (DE) long noncoding RNAs (lncRNAs) between normal and tumor samples of prostate cancer in one Affymetrix dataset and two RNA-seq
datasets (Supplementary Table 1). The Venn diagram shows the number of up-regulated (orange arrow) and down-regulated (blue arrow) DE lncRNAs
identified in one to three datasets. Heatmaps of the normalized Affymetrix expression and normalized RNA-seq log fragments per kilobase of exon per
million fragments mapped (FPKM) of the five DE lncRNAs from all three datasets are shown across normal, tumor, and metastatic samples in each
datasets. Four of the five DE lncRNAs are up-regulated in the tumor dataset and one is down-regulated in all three datasets. Among these five
lncRNAs, PCAT-14 is the only one that shows an association with tumor progression (Supplementary Table 2). (B) Boxplot of normalized Affymetrix
expression of PCAT-14 in Gleason 6 through 9. Expression of PCAT-14 is anticorrelated with Gleason score (correlation [cor] =S0.22). Expression of
PCAT-14 is significantly decreases from Gleason 6 to 9 (p = 0.00013). (C) Boxplot of normalized Affymetrix expression of PCAT-14 in normal, tumor, and
metastatic prostate samples. PCAT-14 is up-regulated in tumor samples compared with normal samples (p = 1.3e-15), and its expression goes down
again in metastatic patients from the tumor dataset (p = 9.7e-06).
E U RO P E AN URO L OGY 7 1 ( 2 0 1 7 ) 2 5 7 – 2 6 6 259progression (Fig. 1C, Supplementary Fig. 1) as exemplified by
PCAT-14 up-regulation in primary tumors compared with
normal tissue (p = 1.3e-15) and PCAT-14 down-regulation in
metastatic relative to primary tumors (p = 9.7e-06).
Notably, PCAT-14 expression is enriched in prostate
cancer as shown in our pan-cancer expression analysis of
6853 specimens across 18 additional solid tumors, as part of
The Cancer Genome Atlas consortium (Supplementary Fig.
2). This is further supported by a recent study reporting
PCAT-14, under the gene alias PRCAT-104, to have altered
expression specifically in prostate cancer [8]. Validation of
PCAT-14 expression in a prostate cancer cell line panel
relative to the control cell line, RWPE, confirmed over-
expression of PCAT-14 in 22Rv1 and VCaP cell lines
(Supplementary Fig. 3A). Subcellular localization revealed
that PCAT-14 is enriched in the nucleus (Supplementary Fig.
3B), which is common amongst lncRNAs associated with
gene regulation.
3.2. Clinical significance of PCAT-14
Given the altered expression of PCAT-14 in prostate cancer,
we hypothesized a potential relationship with clinical
outcomes. Therefore, we assessed PCAT-14 expressionwithin a cohort of 910 radical prostatectomy specimens
from three independent patient cohorts from the Decipher
Genomic Resource Information Database: MCI (N = 545),
MCII (N = 235), and TJU (N = 130). There were 298 total
metastasis events (124 in PCAT-14 high patients, 174 in
PCAT-14 low patients), 166 total deaths from prostate
cancer (69 in PCAT-14 high patients, 97 in PCAT-14 low
patients), and 366 total deaths (175 in PCAT-14 high
patients, 191 in PCAT-14 low patients) in our cohorts.
Patients with high versus low expression of PCAT-14
showed significantly different rates of distant metastasis
free survival (MCI: p = 0.0024, hazard ration
[HR] = 0.66 [0.5–0.86], MCII: p = 0.023, HR = 0.59 [0.37–
0.94], TJU [borderline]: p = 0.093, HR = 0.33 [0.084–1.3]) in
Fig. 2A, overall survival (MCI: p = 0.0044, HR = 0.71 [0.56–
0.9], MCII: p = 0.14, HR = 0.68 [0.41–1.1], TJU: p = 0.0061,
HR = 0.35 [0.16–0.77]) in Fig. 2B, and prostate cancer
specific survival (MCI: p = 0.00059, HR = 0.54 [0.38–0.77],
MCII: p = 0.023, HR = 0.44 [0.22–0.91], TJU [unavailable]) in
Fig. 2C. Consistent with these data, lower PCAT-14 expres-
sion associated with Gleason score as well as lymph node
invasion (Table 1). The prognostic ability of PCAT-14 is
significant even after accounting for clinicopathologic
variables (age, prostate-specific antigen, Gleason, surgical
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Fig. 2 – Prostate cancer associated transcript-14 (PCAT-14) as a single gene predictor of aggressive disease. Kaplan-Meier analyses of prostate cancer
outcomes in the Mayo Clinic cohort. PCAT-14 expression was measured using Affymetrix exon arrays, and participants were stratified according to
PCAT-14 expression. Participant outcomes were analyzed for (A) distant metastasis-free survival, (B) overall survival, and (C) prostate cancer specific
survival, across three patients cohorts (from left to right) Mayo I, Mayo II, and Thomas Jefferson. The p values were calculated using a log-rank test.
The number at risk is shown at the bottom of each plot.
HR = hazard ratio.
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 2 5 7 – 2 6 6260margin status, seminal vesicle invasion, extracapsular
extension, and lymph node invasion) on a pooled multivar-
iable cox analysis (Table 2) of these cohorts (distant
metastasis free survival: p = 0.002, HR = 0.68 [0.53–0.87],
prostate cancer specific survival: p = 0.015, HR = 0.68 [0.53–
0.87], borderline significant for overall survival: p = 0.056,
HR = 0.81 [0.65–1.01]).
Additionally, we investigated if PCAT-14 would improve
the performance of an existing prediction algorithm,
CAPRA-S. We found that when we added PCAT-14 to
CAPRA-S, it increased the receiver operating characteristicarea under the curve for 10-yr metastasis rates from 0.68
(CAPRA-S alone) to 0.70 (CAPRA-S + PCAT-14, p = 0.0185;
Supplementary Fig. 4).
3.3. High PCAT-14 expression promotes a less aggressive
phenotype in vitro
To elucidate the mechanisms of PCAT-14 function, we
utilized our large patient cohort to identify genes with
correlated expression profiles to implicate PCAT-14 in
various biological processes (Supplementary Fig. 5). After
Table 2 – Univariate and multivariate analysis
Univari
p value
DMFS Age 0.76
PSA (int vs low) 0.452
PSA (high vs low) 0.00539
Gleason (int vs low) 0.000805
Gleason (high vs low) 2.70E-09
SMS 0.0616
SVI 6.92E-11
ECE 5.54E-08
LNI 5.65E-08
PCAT14 (high vs low) 1.09E-06
PCSS Age 0.638
PSA (int vs low) 0.386
PSA (high vs low) 0.038
Gleason (int vs low) 0.0536
Gleason (high vs low) 1.29E-06
SMS 0.000617
SVI 2.89E-13
ECE 1.08E-07
LNI 1.85E-12
PCAT14 (high vs low) 6.54E-05
OS Age 1.45E-05
PSA (int vs low) 0.751
PSA (high vs low) 0.011
Gleason (int vs low) 0.00256
Gleason (high vs low) 6.58E-12
SMS 0.000483
SVI 6.34E-09
ECE 9.76E-07
LNI 5.38E-08
PCAT14 (high vs low) 0.00019
CI = conﬁdence interval; DMFS = distant metastasis-free survival; ECE = extracap
survival; PCAT-14 = Prostate Cancer Associated Transcript-14; PCSS = prostate can
status; SVI = seminal vesical involvement.
Table 1 – Demographics in pooled cohort
High PCAT-14 Low PCAT-14 Total p value
Age (yr) 63.8  7.07 64.2  6.91 64  6.99 0.38
Missing 0 0 0
PSA <10 250 (0.549) 243 (0.534) 493 (0.542) 0.813
PSA 10–20 98 (0.215) 106 (0.233) 204 (0.224)
PSA >20 95 (0.209) 96 (0.211) 191 (0.21)
Missing 12 (0.026) 10 (0.022) 22 (0.024)
Gleason <7 62 (0.136) 37 (0.081) 99 (0.109) 2.63E-10
Gleason =7 268 (0.589) 196 (0.431) 464 (0.51)
Gleason 8–10 125 (0.275) 221 (0.486) 346 (0.38)
Missing 0 (0) 1 (0.002) 1 (0.001)
Margins  220 (0.484) 190 (0.418) 410 (0.451) 0.0533
Margins + 235 (0.516) 265 (0.582) 500 (0.549)
Missing 0 (0) 0 (0) 0 (0)
SVI  310 (0.681) 292 (0.642) 602 (0.662) 0.234
SVI + 145 (0.319) 163 (0.358) 308 (0.338)
Missing 0 (0) 0 (0) 0 (0)
ECE  224 (0.492) 205 (0.451) 429 (0.471) 0.244
ECE + 230 (0.505) 248 (0.545) 478 (0.525)
Missing 1 (0.002) 2 (0.004) 3 (0.003)
LNI  411 (0.903) 390 (0.857) 801 (0.88) 0.0323
LNI + 43 (0.095) 65 (0.143) 108 (0.119)
Missing 1 (0.002) 0 (0) 1 (0.001)
ECE = extracapsular extension; LNI = lymph node invasion; PCAT-
14 = Prostate Cancer Associated Transcript-14; PSA = prostate-speciﬁc
antigen; SVI = seminal vesical involvement.
E U RO P E AN URO L OGY 7 1 ( 2 0 1 7 ) 2 5 7 – 2 6 6 261ranking all genes according to their correlation value, we
used Gene Set Enrichment Analysis [20] to search for
enrichment across the Molecular Signatures Database
[21]. We found an enrichment of Lys27 of histone
3 methylated target genes among the highest ranked
concepts, which were inversely correlated with PCAT-14
expression (Supplementary Fig. 5). Notably, EZH2 is over-
expressed in metastatic prostate cancer, a marker of
aggressive disease, and is a critical component of the
polycomb repressive complex 2 that methylates Lys27 of
histone 3 to epigenetically silence target genes associated
with metastasis and poor patient outcome [22]. Further-
more, we observed numerous signatures associated with
tumor microenvironment that could also be indicative of
aggressive disease (Supplementary Fig. 5). Building upon
this, and to further support our clinical findings that low
PCAT-14 promotes aggressive disease, we evaluated what
effect changes in PCAT-14 expression had in vitro. Func-
tional significance of PCAT-14 was assessed in aggressive
cell lines, IGR-Cap1 and PC3, with low endogenous
expression of PCAT-14 and well known to metastasize
[[2_TD$DIFF] 3–25], by stably overexpressing the full length PCAT-14
clones.
Our in vitro findings support the clinical observations by
demonstrating increased PCAT-14 expression resulted inate Multivariate
HR (95% CI) p value HR (95% CI)
1 (0.99–1.02) 0.127 0.99 (0.97–1)
1.12 (0.84–1.49) 0.317 0.86 (0.64–1.16)
1.48 (1.12–1.94) 0.914 0.98 (0.72–1.34)
3.69 (1.72–7.93) 0.00651 2.91 (1.35–6.29)
9.93 (4.66–21.16) 1.62E-06 6.64 (3.06–14.39)
1.25 (0.99–1.57) 0.775 1.04 (0.81–1.32)
2.14 (1.7–2.69) 0.000659 1.58 (1.21–2.05)
1.93 (1.52–2.45) 0.0854 1.26 (0.97–1.64)
2.16 (1.63–2.85) 0.289 1.18 (0.87–1.62)
0.56 (0.44–0.71) 0.00201 0.68 (0.53–0.87)
1.01 (0.98–1.03) 0.472 0.99 (0.97–1.02)
1.18 (0.81–1.74) 0.108 0.72 (0.49–1.07)
1.47 (1.02–2.11) 0.0349 0.64 (0.43–0.97)
2.74 (0.98–7.62) 0.183 2.02 (0.72–5.66)
11.79 (4.34–32.01) 2.36E-04 6.82 (2.45–18.96)
1.73 (1.26–2.37) 0.0716 1.35 (0.97–1.87)
3.16 (2.32–4.3) 0.0000276 2.14 (1.5–3.05)
2.42 (1.75–3.36) 0.103 1.34 (0.94–1.92)
3.32 (2.38–4.64) 0.0215 1.57 (1.07–2.29)
0.53 (0.39–0.72) 0.0154 0.67 (0.48–0.93)
1.04 (1.02–1.06) 0.00541 1.03 (1.01–1.05)
1.04 (0.8–1.36) 0.0548 0.77 (0.58–1.01)
1.38 (1.08–1.78) 0.204 0.83 (0.62–1.11)
2.06 (1.29–3.29) 0.0321 1.71 (1.05–2.79)
5.09 (3.2–8.11) 2.86E-07 3.68 (2.24–6.05)
1.46 (1.18–1.8) 0.0397 1.26 (1.01–1.57)
1.86 (1.51–2.29) 0.00385 1.43 (1.12–1.83)
1.72 (1.38–2.14) 0.221 1.16 (0.91–1.48)
2.07 (1.59–2.69) 0.0605 1.33 (0.99–1.79)
0.67 (0.54–0.83) 0.056 0.81 (0.65–1.01)
sular extension; HR = hazard ratio; LNI = lymph node invasion; OS = overall
cer-speciﬁc survival; PSA = prostate-speciﬁc antigen; SMS = surgical margin
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 2 5 7 – 2 6 6262less aggressive phenotypes. In vitro experiments measuring
the mobility of cells overexpressing PCAT-14 show a
decreasedmigratory/invasive capacity of these cells relative
to the parental cell line with low PCAT-14 expression. PCAT-
14 overexpressing IGR-Cap1 cells and empty vector control
IGR-Cap1 cells were plated in serum-free media on a
transwell membrane and allowed to migrate in a modified
Boyden Chamber assay. After 24 h there was a significant
45% decrease in Clone 1 (p  0.00001) and 26% decrease in
Clone 2 (p  0.001) in the migration of PCAT-14 over-
expressing cells compared with control cells (Fig. 3A). This
decrease in migration was also seen in PC3 PCAT-14
overexpressing cells (Fig. 3B). There was at least an 80%
decrease in migrated cells in both PC3 PCAT-14 over-
expressing cell lines compared with the control cell line
(p  0.00001). Further, experiments were conducted with a
Matrigel-coated transwell to further confirm altering PCAT-
14 expression changes the aggressiveness of prostate cell
lines. Similar to migration assays, PCAT-14 overexpression
in both IGR-Cap1 and PC3 cells significantly diminished
cellular invasion compared with the control cell lines
(Supplementary Fig. 6). Similarly, silencing PCAT-14 with a
combination of small interfering RNAs (50% knockdown) in
22Rv1 cells with high endogenous expression resulted in a
137% (p  0.002) increase in migration relative to control
transfected cells (Supplementary Fig. 7). The changes in
migratory and invasive cellular behavior highlight that
changes in expression levels of PCAT-14 in prostate cancer
cause a less (high expression) or more (low expression)
aggressive phenotype. Cellular proliferation was also
monitored as an additional characterization of an aggressive
phenotype. IGR-Cap1 cells overexpressing two different
clones of PCAT-14 showed a 30% decrease in cell growth
relative to control cells at Day 2 (p = 0.001 and p = 0.00001).
The diminished growth in PCAT-14-expressing cells contin-
ued to Day 6with a 16% and 37% change in Clone 1 and Clone
2 cell growth, respectively (Supplementary Fig. 8). Combined
these data indicate that increased PCAT-14 expression
diminishes oncogenic phenotypes in two well-studied
aggressive prostate cancer cell lines; further, silencing
PCAT-14 promotes an aggressive phenotype. Moreover,
these data support the strong clinical observations that
low PCAT-14 expression associates with aggressive disease.
3.4. PCAT-14 association with androgen deprivation therapy
Through Gene Set Enrichment Analysis, we also found that
high PCAT-14 expression had a positive correlation with
genes involved in prostate cancer (Supplementary Fig. 5)
and androgen response (Fig. 4A). We also observed a
moderate correlation (0.49) between PCAT-14 expression
and androgen receptor transcriptional activity (Supplemen-
tary Fig. 9). Therefore, we investigated if PCAT-14 predicted
the response to therapies such as androgen deprivation
therapy (ADT) in the MCI and MCII cohorts. Of 780 patients,
236 underwent postoperative ADT within 1-yr of radical
prostatectomy. We found that the distant metastasis-free
survival prognostic differences between PCAT-14 high and
low expression are increased in patients treated with ADT(p = 0.00082, HR = 0.5 [0.34–0.76]), and these differences
are attenuated in patients without ADT treatment
(p = 0.015, HR = 0.69 [0.51–0.93]) as shown in Figure 4B.
As our cohorts are all retrospective, which confounds
treatment by baseline risk, it is necessary to adjust for
clinical and pathologic variables and other treatments such
as radiotherapy. In our multivariate Cox model, which
accounts for these confounders, we found statistically
significant interaction terms for ADT and PCAT-14
(p = 0.029) indicating that PCAT-14 can potentially predict
the response to ADT after prostatectomy (Supplementary
Table 6). This is supported by PCAT-14 responsiveness to
testosterone and R1881 in VCaP cells (Supplementary Fig.
10). After androgen deprivation, VCaP cells were treated
with either 10 nM testosterone or 5 nM of R1881. Therewas
a six-fold and approximately four-fold increase in PCAT-14
expression with testosterone and R1881 treatment, respec-
tively, relative to no treatment control. As a positive control,
therewas also a robust increase in TMPRSS2 gene expression
with both drug treatments.
4. Discussion
Our integrative analysis led us to discover a subset of
lncRNAs consistently altered across prostate cancer
patients suggesting their significance in prostate cancer
etiology. Notably, the Ren et al cohort [7] is comprised of
Chinese patients suggesting that these five lncRNAs are
altered independent of ethnicity. The importance of these
lncRNAs is exemplified by a recent study showing that
DRAIC plays a tumor-suppressive role, displays decreased
expression in prostate cancer cell progression from andro-
gen-dependent to a castration-resistant state, and inhibits
cellular migration and invasion [9]. Less is known about the
remaining candidates that were only recently discovered
and reported to have altered expression during prostate
tumorigenesis [6,8] or are not yet associated with prostate
cancer (ie, LOC283177). However, PCAT-14 was the only
candidate that showed an inverse relationshipwith Gleason
score suggestive of its role in suppressing aggressive
disease, and therefore represents an ideal candidate to
investigate.
Herein, we show that PCAT-14 is overexpressed in
prostate tumors and that lower PCAT-14 expression
associates with three clinical endpoints (distant metasta-
sis-free survival, prostate cancer specific survival, and
overall survival). Supporting our clinical findings, we have
provided experimental data highlighting the biological role
of PCAT-14 in prostate cancer. Firstly, using patient data we
were able to associate low PCAT-14 expression with
biological concepts associated with aggressive disease.
Secondly, we demonstrated that PCAT-14 suppresses
metastatic phenotypes in vitro and appears to lose
expression in metastatic samples. Stably overexpressing
PCAT-14 in both IGR-Cap1 and PC3 cells resulted in
significantly less cellular mobility relative to respective
control cell lines. Moreover, the opposite effect—a more
oncogenic phenotype—was observed in PCAT-14 silenced
22Rv1 cells. Taken together, this represents the first study
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Fig. 3 – Overexpression of Prostate Cancer Associated Transcript-14 (PCAT-14) diminishes cellular migration in vitro. (A) IGR-Cap1 or (B) PC3 cells were
plated for 24 h on a transwell membrane. Migrated cells (bottom of filter) were stained with 40 ,6-diamidino-2-phenylindole and quantified.
Quantitative reverse transcription polymerase chain reaction confirmed the overexpression of PCAT-14 in both cell lines relative to empty vector
control cell lines.
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Fig. 4 – Prostate Cancer Associated Transcript-14 (PCAT-14) is predictive of androgen deprivation therapy response. (A) Gene set enrichment analysis of
genes coexpressed with PCAT-14 revealed gene signatures associated with androgen response. Enrichment Score (ES) and false discovery rate (FDR) q-
value are shown within the gene set enrichment analysis plot. (B) Kaplan-Meier curves show that high PCAT-14 expression is differentially prognostic
of distant metastasis-free survival in patients treated with (left) and without (right) androgen deprivation therapy.
HR = hazard ratio.
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prostate cancer as well as the clinical significance of low
PCAT-14 expression for predicting outcome.
Notably, we observed that patients who received ADT
appeared to have a greater distant metastasis-free survival
prognostic difference between PCAT-14 high and low
expression in comparison to patients that did not receive
ADT. As these are retrospective studies, there are inherent
differences between patients that received treatment and
those that did not receive treatment. However, ourmultivariate interaction analysis coupled with the in vitro
data demonstrating that PCAT-14 is androgen responsive
suggests that PCAT-14warrants further study as a predictive
marker for ADT response.
5. Conclusions
Overall, we discovered that PCAT-14 is commonly up-
regulated in primary tumors. Furthermore, low PCAT-14
expression promotes aggressive oncogenic phenotypes and
E U RO P E AN URO L OGY 7 1 ( 2 0 1 7 ) 2 5 7 – 2 6 6 265is significantly prognostic for multiple clinical endpoints. In
addition to predicting metastatic disease, we found that
PCAT-14 may be able to predict ADT response highlighting
its potential use for improving patient management and
prognosis.
Author contributions: Christopher A.Maher had full access to all the data
in the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: White, Zhao, Maher.
Acquisition of data: Zhao, Zhang, White, Alshalalfa, Erho, Rozycki,
McFadden, Dang, Karnes, Den, Davicioni.
Analysis and interpretation of data: White, Zhao, Zhang, Dang, Alshalalfa,
Vergara, Erho, Eteleeb, Maher.
Drafting of the manuscript: White, Zhao, Maher.
Critical revision of the manuscript for important intellectual content:White,
Zhao, Maher.
Statistical analysis: Zhao, Alshalalfa, Vergara, Erho, Zhang.
Obtaining funding: Maher.
Administrative, technical, or material support: Arbeit.
Supervision: Maher.
Other: None.
Financial disclosures: Christopher A. Maher certiﬁes that all conﬂicts of
interest, including speciﬁc ﬁnancial interests and relationships and
afﬁliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/afﬁliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents ﬁled, received, or pending), are the following: Zhao and Karnes
have received travel expenses from GenomeDx Biosciences Inc. Karnes
has received research funding from GenomeDx Biosciences Inc.
Davicioni, Alshalalfa, Vergara, and Erho are employees of GenomeDx
Biosciences.
Funding/Support and role of the sponsor: This study was supported by
Prostate Cancer Foundation Young Investigator Awards (to Christo-
pher A. Maher and Shuang G. Zhao), a V Foundation for Cancer
Research V Scholar Award (to Christopher A. Maher), and a Cancer
Research Foundation Young Investigator Award (to Christopher A.
Maher).
[1_TD$DIFF]Acknowledgments: We thank Anne Chauchereau (INSERM U981,
Villejuif, France) for providing the IGR-CaP1 cells.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at [2_TD$DIFF]http://dx.doi [3_TD$DIFF].org/10.1016/j.
eururo [4_TD$DIFF].2016.07.012.
References
[1] Thompson I, Thrasher JB, Aus G, et al. Guideline for the manage-
ment of clinically localized prostate cancer: 2007 update. J Urol
2007;177:2106–31. http://dx.doi.org/10.1016/j.juro.2007.03.
003.
[2] Malhotra S, Lapointe J, Salari K, et al. A tri-marker proliferation
index predicts biochemical recurrence after surgery for prostate
cancer. PLoS One 2011;6:e20293. http://dx.doi.org/10.1371/
journal.pone.0020293.
[3] Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome
in clinically localised prostate cancer: analysis of conservativelytreated prostate cancer patients from the Trans-Atlantic Prostate
Group study. Br J Cancer 2009;100:888–93. http://dx.doi.org/10.
1038/sj.bjc.6604951.
[4] de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very
sensitive and speciﬁc marker to detect prostate tumors. Cancer Res
2002;62:2695–8, publication date: 2002 May 1.
[5] Prensner JR, Zhao S, Erho N, et al. RNA biomarkers associated with
metastatic progression in prostate cancer: a multi-institutional high-
throughput analysis of SChLAP1. Lancet Oncol 2014;15:1469–80.
http://dx.doi.org/10.1016/S1470-2045(14)71113-1.
[6] Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing
across a prostate cancer cohort identiﬁes PCAT-1, an unannotated
lincRNA implicated in disease progression. Nat Biotechnol
2011;29:742–9. http://dx.doi.org/10.1038/nbt.1914.
[7] Ren S, Peng Z, Mao JH, et al. RNA-seq analysis of prostate cancer in
the Chinese population identiﬁes recurrent gene fusions, cancer-
associated long noncoding RNAs and aberrant alternative splicings.
Cell Res 2012;22:806–21. http://dx.doi.org/10.1038/cr.2012.30.
[8] Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding
RNAs in the human transcriptome. Nat Genet 2015;47:199–208.
http://dx.doi.org/10.1038/ng.3192.
[9] Sakurai K, Reon BJ, Anaya J, Dutta A. The lncRNA DRAIC/PCAT29
locus constitutes a tumor-suppressive nexus. Mol Cancer Res
2015 May;13:828–38. http://dx.doi.org/10.1158/1541-7786.
MCR-15-0016-T.
[10] Malik R, Patel L, Prensner JR, et al. The lncRNA PCAT29 inhibits
oncogenic phenotypes in prostate cancer. Mol Cancer Res
2014;12:1081–7. http://dx.doi.org/10.1158/1541-7786.MCR-14-
0257.
[11] Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic
proﬁling of human prostate cancer. Cancer Cell 2010;18:11–22.
http://dx.doi.org/10.1016/j.ccr.2010.05.026.
[12] Kannan K, Wang L, Wang J, et al. Recurrent chimeric RNAs enriched
in human prostate cancer identiﬁed by deep sequencing. Proc Natl
Acad Sci U S A 2011;108:9172–7. http://dx.doi.org/10.1073/pnas.
1100489108.
[13] Brase JC, Johannes M, Mannsperger H, et al. TMPRSS2-ERG-speciﬁc
transcriptional modulation is associated with prostate cancer bio-
markers and TGF-b signaling. BMC Cancer 2011;11:507. http://dx.
doi.org/10.1186/1471-2407-11-507.
[14] Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a
prostate cancer genomic classiﬁer that predicts early metastasis
following radical prostatectomy. PLoS One 2013;8:e66855. http://
dx.doi.org/10.1371/journal.pone.0066855.
[15] Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic
classiﬁer that predicts metastasis following radical prostatectomy
in an at risk patient population. J Urol 2013;190:2047–53. http://
dx.doi.org/10.1016/j.juro.2013.06.017.
[16] Den RB, Feng FY, Showalter TN, et al. Genomic prostate cancer
classiﬁer predicts biochemical failure and metastases in patients
after postoperative radiation therapy. Int J Radiat Oncol Biol
Phys 2014;89:1038–46. http://dx.doi.org/10.1016/j.ijrobp.2014.
04.052.
[17] Punnen S, Freedland SJ, Presti Jr JC, et al. Multi-institutional vali-
dation of the CAPRA-S score to predict disease recurrence and
mortality after radical prostatectomy. Eur Urol 2014;65:1171–7.
http://dx.doi.org/10.1016/j.eururo.2013.03.058.
[18] CooperbergMR, Hilton JF, Carroll PR. The CAPRA-S score: A straight-
forward tool for improved prediction of outcomes after radical
prostatectomy. Cancer 2011;117:5039–46. http://dx.doi.org/10.
1002/cncr.26169.
[19] McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommen-
dations for tumor MARKer prognostic studies (REMARK). Nat Clin
Pract Oncol 2005;2:416–22, 2005 Aug.
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 2 5 7 – 2 6 6266[20] Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-
wide expression proﬁles. Proc Natl Acad Sci U S A 2005;102:
15545–50. http://dx.doi.org/10.1073/pnas.0506580102.
[21] Liberzon A, Subramanian A, Pinchback R, Thorvaldsdo´ttir H,
Tamayo P, Mesirov JP. Molecular signatures database (MSigDB)
3.0. Bioinformatics 2011;27:1739–40. http://dx.doi.org/10.1093/
bioinformatics/btr260.
[22] Yu J, Yu J, Rhodes DR, et al. A polycomb repression signature
in metastatic prostate cancer predicts cancer outcome. Cancer
Res 2007;67:10657–63. http://dx.doi.org/10.1158/0008-5472.
CAN-07-2498.[23] Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establish-
ment and characterization of a human prostatic carcinoma cell line
(PC-3). Invest Urol 1979;17:16–23, 1979 Jul.
[24] Al Nakouzi N, Bawa O, Le Pape A, et al. The IGR-CaP1 xenograft
model recapitulates mixed osteolytic/blastic bone lesions ob-
served in metastatic prostate cancer. Neoplasia 2012;14:376–87,
2012 May;14.
[25] Chauchereau A, Al Nakouzi N, Gaudin C, et al. Stemness markers
characterize IGR-CaP1, a new cell line derived from primary epi-
thelial prostate cancer. Exp Cell Res 2011;317:262–75. http://dx.
doi.org/10.1016/j.yexcr.2010.10.012.
